Observational studyResearch and practice in thrombosis and haemostasis2026
Preparative leukapheresis impairs autologous donor hemostasis and platelet function.
Observational study in Research and practice in thrombosis and haemostasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Preparative apheresis is performed to produce blood or stem cell products. A rare but serious complication is bleeding due to the inherent loss of platelets and coagulation factors. Objectives: The aim of this study was to provide a comprehensive analysis of hemostasis in autologous donors undergoing preparative apheresis and to assess bleeding complications in this cohort. Methods: In this prospective observational study, a large panel of cellular components and coagulation factors was quantified both immediately before and after apheresis of hematopoietic stem cells ( Results: Postapheresis, we observed a small decrease (5.9%) in prothrombin time, while international normalized ratio, partial thromboplastin time, and thrombin time remained unaffected. Single component analysis revealed a median loss of factor (F)XIII of 15%, fibrinogen of 17.9%, antithrombin of 13.9%, von Willebrand factor (VWF) antigen of 18.7% and VWF activity of 18.2%. In terms of cellular components, we found a median reduction of 25.6% in platelet count, 19.4% reduction in leukocyte count, and 7.1% in hemoglobin level. Platelet aggregation after stimulation with arachidonic acid, adenosine diphosphate, and thrombin-activated peptide-6 was reduced. One patient (1.3%) with evident FXIII deficiency developed minor bleeding and required surgical intervention. Conclusion: Our analysis shows that hemostasis and platelet function are compromised after apheresis in autologous donors, despite mostly unaltered global coagulation parameters. These findings may be of value in the clinical management of apheresis, particularly regarding procedure-related bleeding events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.